Equity Research Surgical & Medical Instruments & Apparatus

Should You Buy Delcath Systems, Inc. Stock in 2026?

By CirclFi Research Team · · 13/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Delcath Systems, Inc. (DCTH) carries a solid Quality of Company rating of 5.9/10. Trading at $12.81, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.

The short answer: 0 of 13 CirclFi valuation models project upside for Delcath Systems, Inc. (DCTH) at $12.81 — the model consensus leans bearish, with a Quality Score of 5.9/10 and Value-Trap risk of 18/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 13 of 13 models suggest overvaluation — majority bearish
  • Quality Score: 5.9/10 — Moderate — mixed signals
  • Value Trap Risk: 18/100 — Minimal — healthy fundamentals
  • Fair Value Range: $1.48 – $12.51 (745% spread)

Bullish Models

0 / 13

Bearish Models

13 / 13

Quality Score

5.9 /10

Moderate — mixed signals

Value Trap Risk

18 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

13 /13
Active Models

Avg. confidence: 37%

Investment Thesis

The Bull Case

Currently, no active models project meaningful upside for DCTH at $12.81. Bulls might argue that qualitative factors not captured by quantitative models could unlock value not reflected in current estimates.

The Bear Case

Target: $1.48 (-88.4%)

  • According to the CirclFi Deep Alpha Valuation Engine, the Sentiment SOTP model sees the stock as overvalued with a fair value of $1.48 (-88.4%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +86.1% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.

Peer Benchmarking

DXCM DexCom, Inc.
10.0
IRMD iRadimed Corporation
10.0
PODD Insulet Corporation
10.0
RMD ResMed Inc.
10.0
WST West Pharmaceutical
9.9

See full Surgical & Medical Instruments & Apparatus rankings →

Valuation Divergence

Spread

745%

Fair Value Range

$1.48 – $12.51

A 745% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

PWERM

$12.51 (-2.4%)

Most Bearish

Sentiment SOTP

$1.48 (-88.4%)

Key Risk Factors

Model Disagreement

745% spread signals high variance in projections.

Bearish Consensus

13/13 models suggest overvaluation.

Macro/Sector Risk

Surgical & Medical Instruments & Apparatus headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View DCTH Data Page →

The Bottom Line

Our valuation engine sends a clear cautionary signal on Delcath Systems, Inc. at $12.81. 12/13 models flag overvaluation, composite fair value sits at $4.44 (-65.4%), and the risk-reward profile appears unfavorable. Quality at 5.9/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Delcath Systems, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy DCTH stock right now?

Based on CirclFi's multi-model analysis, 0 of 13 models see upside for DCTH at $12.81. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Delcath Systems, Inc.?

Key risks include: wide model disagreement (745% spread), signaling high uncertainty; general market and sector-specific risks affecting Surgical & Medical Instruments & Apparatus companies. Always diversify and consult a financial advisor.

How does DCTH compare to its competitors?

Among Surgical & Medical Instruments & Apparatus peers, DCTH holds a Quality Score of 5.9/10. Comparable companies include DXCM (QOC 10.0), IRMD (QOC 10.0), PODD (QOC 10.0). The relative ranking helps investors identify whether DCTH offers better fundamental quality than alternatives in the same sector.

Is DCTH a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. DCTH's Quality Score of 5.9/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy DCTH at?

CirclFi does not provide target buy prices or price alerts. However, our 13 active models produce fair value estimates ranging from $1.48 to $12.51. At $12.81, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for DCTH.

View DCTH Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →